-
Catalpol’s Multi-Pathway Actions in Diabetes and Its Complic
2026-05-25
This review analyzes the pharmacological basis and experimental evidence for Catalpol as a multi-target iridoid glycoside in models of diabetes and diabetic complications. The paper highlights unique pathway modulations and pharmacokinetics, with implications for translational research in metabolic and neuroprotection fields.
-
Repurposing Paroxetine: Inhibiting MET and ERBB3 in Colon Ca
2026-05-25
This study demonstrates that paroxetine, a selective serotonin reuptake inhibitor, directly suppresses human colorectal cancer cell proliferation and tumor growth by inhibiting the MET and ERBB3 kinases. The findings highlight a promising drug repositioning approach and clarify molecular mechanisms for targeting colorectal cancer.
-
GDC-0941 (SKU A8210): Reliable PI3K Inhibitor for Cell Assay
2026-05-24
This article presents scenario-driven guidance for optimizing cell viability, proliferation, and cytotoxicity assays using GDC-0941 (SKU A8210). Drawing on experimental data and practical lab challenges, we demonstrate how this selective PI3K inhibitor delivers reproducible PI3K/Akt pathway inhibition and robust performance in cancer research workflows.
-
Phenacetin in Advanced Pharmacokinetic Models: Protocols & I
2026-05-23
Phenacetin (N-(4-ethoxyphenyl)acetamide) has re-emerged as a gold-standard probe for translational pharmacokinetic studies, especially in hiPSC-derived intestinal organoid systems. This article demystifies experimental workflows, troubleshooting, and evidence-based protocol design, leveraging APExBIO's ultra-pure Phenacetin for maximum scientific impact.
-
Phenacetin in Pharmacokinetic Research: Protocols & Innovati
2026-05-22
Phenacetin (N-(4-ethoxyphenyl)acetamide) is a gold-standard probe for pharmacokinetic studies, prized for its well-defined solubility and purity. This article delivers actionable protocols, troubleshooting strategies, and insights from recent advances that set Phenacetin apart for cutting-edge scientific research use.
-
CPSIT_0844 Drives IL-6/IL-8 via TLR2/4 and JNK in Monocytes
2026-05-22
This study identifies the Chlamydia psittaci inclusion membrane protein CPSIT_0844 as a specific bacterial factor that triggers robust IL-6 and IL-8 production in human monocytes via TLR2/TLR4-MyD88 signaling, with downstream activation of MAPK and NF-κB pathways. These insights clarify a key mechanism underlying C. psittaci-induced inflammation and highlight potential molecular intervention points for inflammation research.
-
FH1-Fueled iHeps: Catalyzing Translational Progress in Liver
2026-05-21
Explore how FH1 small molecule advances iPS-derived hepatocyte maturation, bridging mechanistic insight and translational guidance for next-generation liver cell therapies. Learn how optogenetic gene switches and enhanced hepatocyte function converge, with actionable workflow advice and a strategic outlook for researchers.
-
ZCL278: Selective Cdc42 Inhibitor for Cell Motility Studies
2026-05-21
Harness ZCL278, a selective Cdc42 inhibitor, to dissect cell motility, neuronal branching, and fibrotic signaling with precision. This guide delivers stepwise protocols, troubleshooting tactics, and cross-disciplinary insights to unlock the full translational impact of ZCL278 in advanced cellular research.
-
ROS-Responsive Nanoparticles Induce Cuproptosis for Cancer I
2026-05-20
This study introduces a ROS-sensitive nanoparticle system co-delivering elesclomol and copper to selectively induce cuproptosis in cancer cells, enhancing immune response when combined with αPD-L1 therapy. The findings establish a novel strategy for overcoming immunotherapy resistance and highlight advanced ROS quantification as an essential tool in mechanistic cancer research.
-
Oteseconazole (VT-1161): Enhanced Workflows for Candida Rese
2026-05-20
Oteseconazole (VT-1161) delivers potent, selective inhibition of fungal CYP51, enabling next-generation assays targeting Candida—including resistant strains. This article details actionable workflows, troubleshooting guidance, and protocol parameters to maximize experimental rigor with Oteseconazole from APExBIO.
-
Biomimetic Chromatography Models for Pulmonary Drug Permeabi
2026-05-19
This study pioneers a comparative evaluation of biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane liquid chromatography (IAM-LC), both coupled with mass spectrometry, for modeling lung permeability of pharmaceuticals. The findings reveal nuanced strengths and limitations of each technique, providing valuable guidance for high-throughput permeability screening in respiratory drug development.
-
ATM-Targeted TACE Silencing Reduces Obesity-Induced Diabetes
2026-05-19
This study demonstrates that targeted gene silencing of TACE in visceral adipose tissue macrophages, using the ATS-9R peptide, effectively attenuates obesity-driven inflammation and improves insulin sensitivity in a mouse model. The findings establish a mechanistically precise, non-viral approach for metabolic disease intervention that outperforms nonspecific delivery methods.
-
CD28-ARS2 Axis and PKM Splicing Enable CD8+ T Cell Metabolic
2026-05-18
This study uncovers how the CD28-ARS2 signaling axis governs alternative splicing of pyruvate kinase (PKM), enabling metabolic flexibility in CD8+ T cells and supporting antitumor immunity. The findings reveal a previously unknown layer of post-transcriptional metabolic regulation, opening avenues for targeted immunometabolic interventions.
-
Fluorescein Tyramide: Reliable Signal Amplification in Cell
2026-05-18
This article addresses common challenges in cell viability and molecular detection assays, demonstrating how Fluorescein Tyramide (SKU K1084) delivers reproducible, ultrasensitive signal amplification. Bench-tested protocol guidance and real-world scenario analysis help biomedical researchers, technicians, and postgraduate scientists optimize assay performance using this robust fluorescent labeling dye.
-
Ranolazine in Cardiac Ischemia Research: Protocols and Insig
2026-05-17
Ranolazine’s dual metabolic and electrophysiological actions empower cardiac ischemia research with reproducible, translational workflows. This article distills advanced protocol enhancements and troubleshooting strategies, with a spotlight on Ranolazine’s unique value for metabolic modulation in both cardiac and hepatic models.